Sanmenxia Central Hospital of Henan Province, Henan 472000, China.
J Healthc Eng. 2021 Aug 10;2021:8836288. doi: 10.1155/2021/8836288. eCollection 2021.
The incidence rate of thyroid disease is increasing rapidly worldwide, and the number of thyroid patients is increasing. In this study, serum TAP (tumor abnormal protein) and CEA (carcinoembryonic antigen) were used to detect patients with thyroid nodules of class IV and above to explore the value of serum TAP combined detection of CEA in the risk assessment of thyroid cancer. In this paper, 400 patients with thyroid nodules above class IV diagnosed by physical examination in our hospital health management center from January 2019 to June 2021 were included in the study. Combined with the pathological test results, the patients were divided into risk groups. At the same time, different groups of serum TAP and CEA levels were detected by aggregation and electrochemiluminescence methods, and serum TAP and CEA levels were analyzed according to the pathological diagnostic indicators of CEA levels. The results showed that the levels of serum TAP and CEA in patients with thyroid cancer were significantly higher than those in patients with benign thyroid diseases, and the difference was statistically significant ( < 0.05). The sensitivity, specificity, and AUC under the ROC curve area of serum TAP were 85.25%, 85.06%, and 0.605, respectively. The sensitivity, specificity, and AUC under the ROC curve area of serum CEA were 89.85%, 88.00%, and 0.627, respectively. The sensitivity, specificity, and AUC under the ROC curve area of serum TAP combined with CEA were 96.84%, 96.79%, and 0.915, respectively. Therefore, the combined detection of serum TAP and CEA has a high early screening value in thyroid cancer.
全球范围内甲状腺疾病的发病率正在迅速上升，甲状腺患者的数量也在不断增加。本研究采用血清 TAP（肿瘤异常蛋白）和 CEA（癌胚抗原）检测甲状腺结节Ⅳ级以上患者，探讨血清 TAP 联合 CEA 检测在甲状腺癌风险评估中的价值。本文选取我院健康管理中心 2019 年 1 月至 2021 年 6 月体检诊断为Ⅳ级以上甲状腺结节的 400 例患者为研究对象，结合病理检验结果将患者分为风险组，同时采用聚集和电化学发光法检测不同组患者的血清 TAP 和 CEA 水平，并根据 CEA 水平的病理诊断指标对血清 TAP 和 CEA 水平进行分析。结果显示，甲状腺癌患者血清 TAP 和 CEA 水平明显高于良性甲状腺疾病患者，差异有统计学意义（ < 0.05）。血清 TAP 的 ROC 曲线下面积的敏感度、特异度和 AUC 分别为 85.25%、85.06%和 0.605，血清 CEA 的 ROC 曲线下面积的敏感度、特异度和 AUC 分别为 89.85%、88.00%和 0.627，血清 TAP 联合 CEA 的 ROC 曲线下面积的敏感度、特异度和 AUC 分别为 96.84%、96.79%和 0.915。因此，血清 TAP 和 CEA 联合检测对甲状腺癌具有较高的早期筛查价值。
